Thrombotargets internal discovery focus on Haemostasis and Thrombotic diseases is driven by a number of reasons:
Antihemorrhagic standard drugs available in the market, such as recombinant human clotting factors and plasma concentrated coagulation factors, show a large list of problems (i.e. intravenous administration with multiple dosing, generation of antibodies, damage due to delays in treatment, viruses, etc). However, no topical antihemorrhagic standard drug is available. We are convinced that patients with Defective Coagulation Factors (Haemophilia, von Willebrand disease, etc) will prefer topical rather than intravenous administrations. Therefore, growth opportunities for topic hemostatic drugs able to stop bleeding after moderate or severe injury are provided by a large population of both healthy patients and of patients with a specific defective coagulation factor.
Heparins and cumarinic drugs, the standards of care for thrombosis, have serious side-effects and monitoring is required, whereas newer anti Factor Xa drugs have safety concerns. Our new biological drugs have validated certain new coagulation pathways and targets for which small molecule therapeutics may be the best therapeutic solution.